ES2101237T3 - Factor-4 plaquetario modificado. - Google Patents
Factor-4 plaquetario modificado.Info
- Publication number
- ES2101237T3 ES2101237T3 ES93307592T ES93307592T ES2101237T3 ES 2101237 T3 ES2101237 T3 ES 2101237T3 ES 93307592 T ES93307592 T ES 93307592T ES 93307592 T ES93307592 T ES 93307592T ES 2101237 T3 ES2101237 T3 ES 2101237T3
- Authority
- ES
- Spain
- Prior art keywords
- mpf
- platelet factor
- cpf
- factor
- potent
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/521—Chemokines
- C07K14/522—Alpha-chemokines, e.g. NAP-2, ENA-78, GRO-alpha/MGSA/NAP-3, GRO-beta/MIP-2alpha, GRO-gamma/MIP-2beta, IP-10, GCP-2, MIG, PBSF, PF-4, KC
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Gastroenterology & Hepatology (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Toxicology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Saccharide Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Detergent Compositions (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
- Materials For Medical Uses (AREA)
Abstract
LA INVENCION SE BASA EN EL DESCUBRIMIENTO DE DOS FORMAS MODIFICADAS DEL FACTOR 4 DE LAS PLAQUETAS HUMANAS, AQUI LLAMADAS MPF-4 Y CPF-4, QUE FUERON AISLADAS A PARTIR DE UN MEDIO DE CULTIVO LIBRE DE SUERO DE LEUCOCITOS DE LA SANGRE PERIFERICO ESTIMULADOS CON LIPOPOLISACARIDOS. LA DETERMINACION DE LA SECUENCIA DE AMINOACIDO HA REVELADO QUE EL MPF-4 COMPARTE HOMOLOGIAS CON EL FACTOR 4 DE LAS PLAQUETAS COMENZANDO EN EL RESIDUO 17 N TERMINAL. EL CPF-4 CONSTA DE DISULFURO DE MPF-4 UNIDO A LOS 16 RESIDUOS N TERMINAL N DEL FACTOR 4 DE LAS PLAQUETAS. TANTO EL MPF-4 COMO EL CPF-4 SON POTENTES INHIBIDORES EN LA PROLIFERACION DE CELULAS ENDOTELIALES, ENTRE 10 Y 100 VECES MAS POTENTE QUE NATIVO O EL FACTOR 4 RECOMBINANTE DE LAS PLAQUETAS, HACIENDOLOS UTILES EN EL TRATAMIENTO DE ENFERMEDADES ANGIOGENICAS.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US95279792A | 1992-09-25 | 1992-09-25 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2101237T3 true ES2101237T3 (es) | 1997-07-01 |
Family
ID=25493243
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES93307592T Expired - Lifetime ES2101237T3 (es) | 1992-09-25 | 1993-09-24 | Factor-4 plaquetario modificado. |
Country Status (24)
| Country | Link |
|---|---|
| US (3) | US5538949A (es) |
| EP (1) | EP0589719B1 (es) |
| JP (1) | JPH06220091A (es) |
| KR (1) | KR940007059A (es) |
| CN (1) | CN1035257C (es) |
| AT (1) | ATE151777T1 (es) |
| AU (1) | AU665114B2 (es) |
| BR (1) | BR9303903A (es) |
| CA (1) | CA2106629A1 (es) |
| CZ (1) | CZ195193A3 (es) |
| DE (1) | DE69309827T2 (es) |
| DK (1) | DK0589719T3 (es) |
| ES (1) | ES2101237T3 (es) |
| FI (1) | FI934183A (es) |
| GR (1) | GR3023356T3 (es) |
| HK (1) | HK100597A (es) |
| HU (1) | HUT69928A (es) |
| IL (1) | IL107040A0 (es) |
| MX (1) | MX9305901A (es) |
| MY (1) | MY109158A (es) |
| NO (1) | NO933423L (es) |
| NZ (1) | NZ248724A (es) |
| YU (1) | YU61893A (es) |
| ZA (1) | ZA936925B (es) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ZA936925B (en) * | 1992-09-25 | 1995-03-20 | Lilly Co Eli | Modified platelet factor-4. |
| IL113561A0 (en) * | 1994-05-09 | 1995-08-31 | Lilly Co Eli | Expression of recombinant mpf-4, cpf-4, pf-4 and precursor compounds |
| US5994292A (en) * | 1995-05-31 | 1999-11-30 | The United States Of America As Represented By The Department Of Health And Human Services | Interferon-inducible protein 10 is a potent inhibitor of angiogenesis |
| JPH09143199A (ja) * | 1995-11-17 | 1997-06-03 | Nippon Chem Res Kk | 血小板第４因子の製造方法 |
| CN101307106B (zh) * | 1995-12-13 | 2013-06-12 | 儿童医学中心公司 | 内皮细胞增殖抑制剂及其应用方法 |
| FR2774990B1 (fr) * | 1998-02-16 | 2000-07-28 | Inst Vaisseaux Et Du Sang | Nouveaux peptides, utilisation en therapeutique et compositions pharmaceutiques les renfermant |
| ES2431362T3 (es) | 2001-09-12 | 2013-11-26 | Sigma-Tau Research Switzerland S.A. | Derivados de glicosaminoglicanos totalmente N-desulfatados como agentes inhibidores de la heparanasa, dotados con actividad antiangiogénica y desprovistos de efecto anticoagulante |
| EP1812468A2 (en) * | 2004-09-15 | 2007-08-01 | K.U.Leuven Research & Development | Platelet factor 4 variant 1 (pf4var1) related inhibitors of angiogenesis |
| CN114805536B (zh) * | 2022-06-24 | 2022-09-02 | 北京百臻生物技术有限公司 | 一种人血小板因子4蛋白突变体及其应用 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4645828A (en) * | 1984-03-23 | 1987-02-24 | Oncogen | Platelet related growth regulator |
| US4737580A (en) * | 1985-03-15 | 1988-04-12 | Oncogen | Platelet related growth regulator |
| US4844895A (en) * | 1985-11-01 | 1989-07-04 | New York University | Composition containing a peptide fragment of platelet factor four and method for restoring suppressed immune responses |
| NZ218634A (en) * | 1985-12-20 | 1991-06-25 | Oncogen | Peptide identified by its cross reactivity with a cell growth factor, dna, antibodies to peptide and test kits |
| AU1539188A (en) * | 1987-05-04 | 1988-11-10 | Bristol-Myers Squibb Company | TGF-B2 and novel compositions having anti-neoplastic activity |
| US5086164A (en) * | 1989-01-10 | 1992-02-04 | Repligen Corporation | Novel methods and compositions for treatment of angiogenic diseases |
| US5187075A (en) * | 1989-01-26 | 1993-02-16 | Sri International | Cloning and expression of a variant gene of platelet factor 4 and compositions thereof to modulate immune responses |
| US5112946A (en) * | 1989-07-06 | 1992-05-12 | Repligen Corporation | Modified pf4 compositions and methods of use |
| EP0423641A3 (en) * | 1989-10-18 | 1992-01-15 | Nippon Mining Company Limited | Expression vector, transformed microorganism, fusion protein and method for the production of platelet factor 4 or tgfalpha |
| WO1992002240A2 (en) * | 1990-07-27 | 1992-02-20 | Repligen Corporation | Novel methods and compositions for treatment of angiogenic diseases |
| ZA936925B (en) * | 1992-09-25 | 1995-03-20 | Lilly Co Eli | Modified platelet factor-4. |
-
1993
- 1993-09-20 ZA ZA936925A patent/ZA936925B/xx unknown
- 1993-09-20 IL IL107040A patent/IL107040A0/xx unknown
- 1993-09-20 CZ CZ931951A patent/CZ195193A3/cs unknown
- 1993-09-21 NZ NZ248724A patent/NZ248724A/en unknown
- 1993-09-21 CA CA002106629A patent/CA2106629A1/en not_active Abandoned
- 1993-09-21 MY MYPI93001916A patent/MY109158A/en unknown
- 1993-09-23 HU HU9302687A patent/HUT69928A/hu unknown
- 1993-09-23 AU AU47573/93A patent/AU665114B2/en not_active Ceased
- 1993-09-24 ES ES93307592T patent/ES2101237T3/es not_active Expired - Lifetime
- 1993-09-24 FI FI934183A patent/FI934183A/fi unknown
- 1993-09-24 MX MX9305901A patent/MX9305901A/es not_active IP Right Cessation
- 1993-09-24 DK DK93307592.1T patent/DK0589719T3/da active
- 1993-09-24 JP JP5237846A patent/JPH06220091A/ja not_active Withdrawn
- 1993-09-24 YU YU61893A patent/YU61893A/sh unknown
- 1993-09-24 BR BR9303903A patent/BR9303903A/pt not_active Application Discontinuation
- 1993-09-24 DE DE69309827T patent/DE69309827T2/de not_active Expired - Fee Related
- 1993-09-24 CN CN93117297A patent/CN1035257C/zh not_active Expired - Fee Related
- 1993-09-24 AT AT93307592T patent/ATE151777T1/de not_active IP Right Cessation
- 1993-09-24 KR KR1019930019607A patent/KR940007059A/ko not_active Application Discontinuation
- 1993-09-24 EP EP93307592A patent/EP0589719B1/en not_active Expired - Lifetime
- 1993-09-24 NO NO933423A patent/NO933423L/no unknown
-
1995
- 1995-05-11 US US08/439,348 patent/US5538949A/en not_active Expired - Fee Related
- 1995-05-11 US US08/439,546 patent/US5512550A/en not_active Expired - Fee Related
-
1996
- 1996-02-14 US US08/601,478 patent/US5935928A/en not_active Expired - Fee Related
-
1997
- 1997-05-09 GR GR970401008T patent/GR3023356T3/el unknown
- 1997-06-26 HK HK100597A patent/HK100597A/xx not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| YU61893A (sh) | 1996-02-19 |
| EP0589719B1 (en) | 1997-04-16 |
| AU4757393A (en) | 1994-03-31 |
| US5935928A (en) | 1999-08-10 |
| AU665114B2 (en) | 1995-12-14 |
| NO933423L (no) | 1994-03-28 |
| HU9302687D0 (en) | 1993-12-28 |
| IL107040A0 (en) | 1993-12-28 |
| GR3023356T3 (en) | 1997-08-29 |
| EP0589719A1 (en) | 1994-03-30 |
| DK0589719T3 (da) | 1997-09-08 |
| DE69309827T2 (de) | 1997-08-28 |
| HK100597A (en) | 1997-08-08 |
| JPH06220091A (ja) | 1994-08-09 |
| BR9303903A (pt) | 1994-06-14 |
| KR940007059A (ko) | 1994-04-26 |
| HUT69928A (en) | 1995-09-28 |
| CA2106629A1 (en) | 1994-03-26 |
| US5538949A (en) | 1996-07-23 |
| CN1035257C (zh) | 1997-06-25 |
| MX9305901A (es) | 1994-05-31 |
| ATE151777T1 (de) | 1997-05-15 |
| ZA936925B (en) | 1995-03-20 |
| CN1088216A (zh) | 1994-06-22 |
| DE69309827D1 (de) | 1997-05-22 |
| NZ248724A (en) | 1995-10-26 |
| FI934183A (fi) | 1994-03-26 |
| CZ195193A3 (en) | 1994-04-13 |
| NO933423D0 (no) | 1993-09-24 |
| MY109158A (en) | 1996-12-31 |
| US5512550A (en) | 1996-04-30 |
| FI934183A0 (fi) | 1993-09-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE3876401D1 (de) | N-terminale fragmente von menschlichem serumalbumin. | |
| ATE110782T1 (de) | Rekombinanter menschlicher endothelzellenwachstumsfaktor. | |
| DE3856189D1 (de) | Adhäsionsvarianten | |
| DK455789D0 (da) | Polypeptid | |
| DE3770915D1 (de) | Menschliches apolipoprotein a1 sowie dessen variante, exprimiert in escherichia coli. | |
| DK0589719T3 (da) | Modificeret blodpladefaktor-4 | |
| BR9007115A (pt) | Novo trombolitico | |
| EP0446315A4 (en) | Recombinant product | |
| ES2058479T3 (es) | Compuestos peptidicos. | |
| ATE143974T1 (de) | Peptide des hiv-gag proteins, ihre herstellung und verwendung | |
| WO1995021916A3 (en) | Pp32: a newly identified cd45-associated protein | |
| ATE123056T1 (de) | Ancrod-proteine, ihre herstellung und verwendung. | |
| RU93054511A (ru) | Тромбоцитарные факторы, фармацевтическая композиция, способ получения тромбоцитарных факторов, днк, вектор, клетка | |
| ATE335817T1 (de) | Adhäsionsvarianten |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG2A | Definitive protection |
Ref document number: 589719 Country of ref document: ES |